Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2014 07:20 ET | Source: Boston Therapeutics

Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes

MANCHESTER, NH--(Marketwired - Sep 16, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
September 15, 2014 08:27 ET | Source: Boston Therapeutics

Boston Therapeutics to Present at National Investment Banking Conference on September 16, 2014

MANCHESTER, NH--(Marketwired - Sep 15, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), developer of complex carbohydrate therapeutics to treat diabetes, announced that David Platt, Ph.D., Chief...
September 05, 2014 08:36 ET | Source: Boston Therapeutics

Boston Therapeutics to Present at Rodman & Renshaw Annual Global Investment Conference on September 10, 2014

MANCHESTER, NH--(Marketwired - Sep 5, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), developer of complex carbohydrate therapeutics to treat diabetes, announced that David Platt, Ph.D.,...
August 20, 2014 08:11 ET | Source: Boston Therapeutics

Boston Therapeutics Completes Enrollment of Patients With Type 2 Diabetes in Phase IIb Study on BTI-320 in the U.S.

MANCHESTER, NH--(Marketwired - Aug 20, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb...
August 18, 2014 07:25 ET | Source: Boston Therapeutics

Boston Therapeutics Appoints Noted Diabetes Specialist Jaime A. Davidson, M.D. to Its Medical Advisory Board

MANCHESTER, NH--(Marketwired - Aug 18, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, has appointed noted diabetes...
August 08, 2014 10:55 ET | Source: Boston Therapeutics

Boston Therapeutics Reports Corporate Update and Financial Results for the Second Quarter Ended June 30, 2014

MANCHESTER, NH--(Marketwired - Aug 8, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of compounds that address diabetes using complex...
August 05, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Expands Medical Advisory Board

MANCHESTER, NH--(Marketwired - Aug 5, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes,...
July 30, 2014 06:30 ET | Source: Boston Therapeutics

Boston Therapeutics to Sponsor Symposium at American Chemical Society's Fall National Meeting in San Francisco

MANCHESTER, NH--(Marketwired - Jul 30, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, is sponsoring a symposium to be held at...
July 29, 2014 06:30 ET | Source: Boston Therapeutics

Boston Therapeutics Appoints Zbigniew J. Witczak, Ph.D., to Its Scientific Advisory Board

MANCHESTER, NH--(Marketwired - Jul 29, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed...
July 09, 2014 07:00 ET | Source: Boston Therapeutics

Boston Therapeutics Appoints Benjamin Rivnay, Ph.D. to Chief Scientist

MANCHESTER, NH--(Marketwired - Jul 9, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed...